MX2022015886A - Derivados de amidopirimidona. - Google Patents

Derivados de amidopirimidona.

Info

Publication number
MX2022015886A
MX2022015886A MX2022015886A MX2022015886A MX2022015886A MX 2022015886 A MX2022015886 A MX 2022015886A MX 2022015886 A MX2022015886 A MX 2022015886A MX 2022015886 A MX2022015886 A MX 2022015886A MX 2022015886 A MX2022015886 A MX 2022015886A
Authority
MX
Mexico
Prior art keywords
sup
amidopyrimidone
derivatives
formula
present
Prior art date
Application number
MX2022015886A
Other languages
English (en)
Inventor
Wolfgang Haap
Hasane Ratni
Luke Green
Buelent Kocer
Claus Riemer
Andreas Kuglstatter
Andrew Simon Bell
Patrizio Mattei
Jérémy BESNARD
Anthony Richard Bradley
Xavier Lucas
Dmitry Mazunin
Hoorn Willem Paul Van
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2022015886A publication Critical patent/MX2022015886A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención proporciona compuestos de fórmula I o II: (ver Fórmulas) en donde X1, X3, R1, R2, R3, R4 y R5 son como se describen en la presente, así como sales farmacéuticamente aceptables de estos. Asimismo, la presente invención se refiere a la elaboración de los compuestos de fórmula I, composiciones farmacéuticas que los comprenden y su uso como medicamentos.
MX2022015886A 2020-06-22 2021-06-21 Derivados de amidopirimidona. MX2022015886A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20181341 2020-06-22
PCT/EP2021/066725 WO2021259815A1 (en) 2020-06-22 2021-06-21 Amidopyrimidone derivatives

Publications (1)

Publication Number Publication Date
MX2022015886A true MX2022015886A (es) 2023-01-24

Family

ID=71120055

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015886A MX2022015886A (es) 2020-06-22 2021-06-21 Derivados de amidopirimidona.

Country Status (18)

Country Link
US (2) US20230227449A1 (es)
EP (1) EP4168394A1 (es)
JP (1) JP7749602B2 (es)
KR (1) KR20230027042A (es)
CN (1) CN115867541A (es)
AR (1) AR122704A1 (es)
AU (1) AU2021295413A1 (es)
BR (1) BR112022026080A2 (es)
CA (1) CA3181790A1 (es)
CL (1) CL2022003646A1 (es)
CO (1) CO2023000056A2 (es)
CR (1) CR20220638A (es)
IL (1) IL297879A (es)
MX (1) MX2022015886A (es)
PE (1) PE20230685A1 (es)
PH (1) PH12022553420A1 (es)
TW (1) TW202216707A (es)
WO (1) WO2021259815A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115215862A (zh) * 2021-04-19 2022-10-21 武汉人福创新药物研发中心有限公司 嘧啶酮化合物及其用途
AR127404A1 (es) 2021-10-20 2024-01-17 Insilico Medicine Ip Ltd Inhibidores de la metionina adenosiltransferasa 2a (mat2a) y usos de los mismos
CN114751856A (zh) * 2022-03-27 2022-07-15 江苏壹药新材料有限公司 一种5-碘-6-甲基烟腈的合成方法
IL318033A (en) * 2022-06-27 2025-02-01 Cspc Zhongqi Pharmaceutical Tech Shijiazhuang Co Ltd Tricyclic compounds and their uses
EP4698523A1 (en) * 2023-04-19 2026-02-25 Insilico Medicine IP Limited Crystalline methionine adenosyltransferase 2a (mat2a) inhibitor and uses thereof
CN116283800B (zh) * 2023-05-16 2023-07-18 英矽智能科技(上海)有限公司 氧代喹唑啉类化合物及其应用
WO2025166260A1 (en) 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Amide substituted tricyclic guanidino compounds as prmt5 inhibitors
WO2025166215A1 (en) 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Triheterocyclic guanidino compounds as prmt5 inhibitors
WO2025166257A1 (en) 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Amide substituted triheterocyclic guanidino compounds as prmt5 inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO440496A0 (en) * 1996-12-30 1997-01-23 Fujisawa Pharmaceutical Co., Ltd. Quinazoline derivatives
JP2001354567A (ja) 2000-04-13 2001-12-25 Nippon Zoki Pharmaceut Co Ltd 皮膚炎治療剤
EP1958666A1 (en) 2007-02-13 2008-08-20 Speedel Experimenta AG Heterocyclic-substituted alkanamides as therapeutic compounds
EP2138482A4 (en) 2007-04-19 2011-06-15 Astellas Pharma Inc BICYCLIC HETEROCYCLIC COMPOUND
US20090227575A1 (en) 2008-03-04 2009-09-10 Wyeth 7H-PYRROLO[2,3-H]QUINAZOLINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESIS
US20100036123A1 (en) 2008-08-07 2010-02-11 Wyeth Process for the preparation of 2,4-dichloro-7h-pyrrolo[2,3h]quinazoline
JP2012518640A (ja) 2009-02-23 2012-08-16 メルク・シャープ・エンド・ドーム・コーポレイション ピラゾロ［４，３−ｃ］シンノリン−３−オンＭ１受容体陽性アロステリックモジュレーター
CN102516339B (zh) 2010-10-21 2014-03-19 四川大学华西医院 嘧啶并嘧啶化合物及其核苷类似衍生物和制备方法及用途
EP3568390B1 (en) 2017-01-10 2024-03-06 Sanford Burnham Prebys Medical Discovery Institute Small molecule activators of nicotinamide phosphoribosyltransferase (nampt) and uses thereof
US12503467B2 (en) * 2018-12-10 2025-12-23 Ideaya Biosciences, Inc. 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors
US20220098203A1 (en) * 2018-12-27 2022-03-31 Les Laboratoires Servier Sas Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
US20220251109A1 (en) 2019-04-28 2022-08-11 Genfleet Therapeutics (Shanghai) Inc. Oxaazaquinazoline-7(8h)-ketone compound, preparation method therefor and pharmaceutical application thereof
US20230257377A1 (en) * 2020-06-10 2023-08-17 Ideaya Biosciences, Inc. 2-aminoquinazolinone derivatives as methionine adenosyltransferase 2a inhibitors

Also Published As

Publication number Publication date
IL297879A (en) 2023-01-01
CO2023000056A2 (es) 2023-03-27
PE20230685A1 (es) 2023-04-21
JP2023531021A (ja) 2023-07-20
BR112022026080A2 (pt) 2023-01-17
AR122704A1 (es) 2022-09-28
KR20230027042A (ko) 2023-02-27
US20230227449A1 (en) 2023-07-20
CR20220638A (es) 2023-01-31
US20240400556A1 (en) 2024-12-05
PH12022553420A1 (en) 2024-04-22
JP7749602B2 (ja) 2025-10-06
CL2022003646A1 (es) 2023-08-04
EP4168394A1 (en) 2023-04-26
CA3181790A1 (en) 2021-12-30
CN115867541A (zh) 2023-03-28
WO2021259815A1 (en) 2021-12-30
AU2021295413A1 (en) 2022-12-01
TW202216707A (zh) 2022-05-01

Similar Documents

Publication Publication Date Title
MX2022015886A (es) Derivados de amidopirimidona.
MX2020007633A (es) Péptidos macrocíclicos contra acinetobacter baumannii.
MX2023001379A (es) Derivados de piperidin-1-il-n-piridina-3-il-2-oxoacet amida utiles para el tratamiento de canceres deficientes en mtap y/o que acumulan mt a.
CR20220371A (es) Agonistas heterocíclicos de glp-1
PH12021551257A1 (en) Cyclic pantetheine derivatives and uses thereof
MX2022010520A (es) Macrociclos peptidicos contra acinetobacter baumannii.
WO2021147236A9 (zh) 取代氨基丙酸酯类化合物在治疗SARS-CoV-2感染中的应用
MX2024009539A (es) Esteroides neuroactivos y composiciones de estos.
GEAP202416435A (en) Anti-viral compounds
PY1923494A (es) Derivados de n-(3-(7h-pirrolo[2,3-d]pirimidin-4-il)fenil)benzamida
ATE440834T1 (de) Substituierte arylaminderivate und verwendungsverfahren
CR20230485A (es) Derivados de fósforo como nuevos inhibidores de sos1
CY1111188T1 (el) Αντιβακτηριακα παραγωγα κινολινης
MX2023004033A (es) Espiro derivados de alfa-d-galactopiranosidos.
MX2022016263A (es) Derivados de ciclobutil-urea.
SA523442503B1 (ar) مشتقات سبيروبيبريدينيل مستبدل بأريل غير متجانس واستخدامات صيدلانية لها
MX2024012967A (es) Derivados de piridina para el tratamiento de los trastornos psiquiatricos
MX2023009954A (es) Compuestos de aminopirimidina y métodos de uso de estos.
MX2023006176A (es) Nuevos derivados de indazol acetileno.
CR20230331A (es) Derivados de pirazolamida
MX2024003015A (es) Nuevos derivados de quinolina.
CR20220644A (es) Derivados de sulfona
BR0110255A (pt) Cromenilmetil pirimidinadiaminas como agentes antibacterianos
MX2022004215A (es) Derivados de 2-azaespiro[3.4]octano como agonistas de m4.
TR200102306T2 (tr) Faktör Xa önleyici olarak heterosiklik türevler.